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Abstract. The classic frequentist theory of hypothesis testing devel-
oped by Neyman, Pearson and Fisher has a claim to being the twenti-
eth century’s most influential piece of applied mathematics. Something
new is happening in the twenty-first century: high-throughput devices,
such as microarrays, routinely require simultaneous hypothesis tests for
thousands of individual cases, not at all what the classical theory had
in mind. In these situations empirical Bayes information begins to force
itself upon frequentists and Bayesians alike. The two-groups model is a
simple Bayesian construction that facilitates empirical Bayes analysis.
This article concerns the interplay of Bayesian and frequentist ideas
in the two-groups setting, with particular attention focused on Ben-
jamini and Hochberg’s False Discovery Rate method. Topics include
the choice and meaning of the null hypothesis in large-scale testing sit-
uations, power considerations, the limitations of permutation methods,
significance testing for groups of cases (such as pathways in microarray
studies), correlation effects, multiple confidence intervals and Bayesian
competitors to the two-groups model.
Key words and phrases: Simultaneous tests, empirical null, false dis-
covery rates.
1. INTRODUCTION
Simultaneous hypothesis testing was a lively re-
search topic during my student days, exemplified by
Rupert Miller’s classic text “Simultaneous Statis-
tical Inference” (1966, 1981). Attention focused on
testing N null hypotheses at the same time, where
N was typically less than half a dozen, though the
requisite tables might go up to N = 20. Modern sci-
entific technology, led by the microarray, has upped
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the ante in dramatic fashion: my examples here will
have N ’s ranging from 200 to 10,000, while N =
500,000, from SNP analyses, is waiting in the wings.
[The astrostatistical applications in Liang et al. (2004)
envision N = 1010 and more!]
Miller’s text is relentlessly frequentist, reflecting
a classic Neyman–Pearson testing framework, with
the main goal being preservation of “α,” overall test
size, in the face of multiple inference. Most of the
current microarray statistics literature shares this
goal, and also its frequentist viewpoint, as described
in the nice review article by Dudoit and Boldrick
(2003).
Something changes, though, whenN gets big: with
thousands of parallel inference problems to consider
simultaneously, Bayesian considerations begin to force
themselves even upon dedicated frequentists. The
“two-groups model” of the title is a particularly sim-
ple Bayesian framework for large-scale testing situa-
tions. This article explores the interplay of frequen-
tist and Bayesian ideas in the two-groups setting,
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Fig. 1. Four examples of large-scale simultaneous inference, each panel indicating N z-values as explained in the text. Panel
A, prostate cancer microarray study, N = 6033 genes; panel B, comparison of advantaged versus disadvantaged students passing
mathematics competency tests, N = 3748 high schools; panel C, proteomics study, N = 230 ordered peaks in time-of-flight
spectroscopy experiment; panel D, imaging study comparing dyslexic versus normal children, showing horizontal slice of 655
voxels out of N = 15,455, coded “−” for zi < 0, “+” for zi ≥ 0 and solid circle for zi > 2.
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with particular attention paid to False Discovery
Rates (Benjamini and Hochberg, 1995).
Figure 1 concerns four examples of large-scale si-
multaneous hypothesis testing. Each example con-
sists of N individual cases, with each case repre-
sented by its own z-value “zi,” for i = 1,2, . . . ,N .
The zi’s are based on familiar constructions that,
theoretically, should yield standard N(0,1) normal
distributions under a classical null hypothesis,
theoretical null :zi ∼N(0,1).(1.1)
Here is a brief description of the four examples, with
further information following as needed in the se-
quel.
Example A [Prostate data, Singh et al. (2002)].
N = 6033 genes on 102 microarrays, n1 = 50 healthy
males compared with n2 = 52 prostate cancer pa-
tients; zi’s based on two-sample t statistics compar-
ing the two categories.
Example B [Education data, Rogosa (2003)].
N = 3748 California high schools; zi’s based on bi-
nomial test of proportion advantaged versus pro-
portion disadvantaged students passing mathemat-
ics competency tests.
Example C [Proteomics data, Turnbull (2006)].
N = 230 ordered peaks in time-of-flight spectroscopy
study of 551 heart disease patients. Each peak’s z-
value was obtained from a Cox regression of the pa-
tients’ survival times, with the predictor variable be-
ing the 551 observed intensities at that peak.
Example D [Imaging data, Schwartzman et al.
(2005]). N = 15,445 voxels in a diffusion tensor
imaging (DTI) study comparing 6 dyslexic with six
normal children; zi’s based on two-sample t statistics
comparing the two groups. The figure shows only
a single horizontal brain section having 655 voxels,
with “−” indicating zi < 0, “+” for zi ≥ 0, and solid
circles for zi > 2.
Our four examples are enough alike to be usefully
analyzed by the two-groups model of Section 2, but
there are some striking differences, too: the theo-
retical N(0,1) null (1.1) is obviously inappropriate
for the education data of panel B; there is a hint
of correlation of z-value with peak number in panel
C, especially near the right limit; and there is sub-
stantial spatial correlation appearing in the imaging
data of panel D.
My plan here is to discuss a range of inference
problems raised by large-scale hypothesis testing,
many of which, it seems to me, have been more or
less underemphasized in a literature focused on con-
trolling Type-I errors: the choice of a null hypothe-
sis, limitations of permutation methods, the mean-
ing of “null” and “nonnull” in large-scale settings,
questions of power, test of significance for groups of
cases (e.g., pathways in microarray studies), the ef-
fects of correlation, multiple confidence statements
and Bayesian competitors to the two-groups model.
The presentation is intended to be as nontechnical
as possible, many of the topics being discussed more
carefully in Efron (2004, 2005, 2006). References will
be provided as we go along, but this is not intended
as a comprehensive review. Microarrays have stim-
ulated a burst of creativity from the statistics com-
munity, and I apologize in advance for this article’s
concentration on my own point of view, which aims
at minimizing the amount of statistical modeling
required of the statistician. More model-intensive
techniques, including fully Bayesian approaches, as
in Parmigiani et al. (2002) or Lewin et al. (2006),
have their own virtues, which I hope will emerge in
the Discussion.
Section 2 discusses the two-groups model and false
discovery rates in an idealized Bayesian setting. Em-
pirical Bayes methods are needed to carry out these
ideas in practice, as discussed in Section 3. This dis-
cussion assumes a “good” situation, like that of Ex-
ample A, where the theoretical null (1.1) fits the
data. When it does not, as in Example B, the em-
pirical null methods of Section 4 come into play.
These raise interpretive questions of their own, as
mentioned above, discussed in the later sections.
We are living through a scientific revolution pow-
ered by the new generation of high-throughput ob-
servational devices. This is a wonderful opportunity
for statisticians, to redemonstrate our value to the
scientific world, but also to rethink basic topics in
statistical theory. Hypothesis testing is the topic
here, a subject that needs a fresh look in contexts
like those of Figure 1.
2. THE TWO-GROUPS MODEL AND FALSE
DISCOVERY RATES
The two-groups model is too simple to have a sin-
gle identifiable author, but it plays an important
role in the Bayesian microarray literature, as in Lee
et al. (2000), Newton et al. (2001) and Efron et al.
(2001). We suppose that the N cases (“genes” as
they will be called now in deference to microarray
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studies, though they are not genes in the last three
examples of Figure 1) are each either null or non-
null with prior probability p0 or p1 = 1 − p0, and
with z-values having density either f0(z) or f1(z),
p0 =Pr{null} f0(z) density if null,
(2.1)
p1 =Pr{nonnull} f1(z) density if nonnull.
The usual purpose of large-scale simultaneous test-
ing is to reduce a vast set of possibilities to a much
smaller set of scientifically interesting prospects. In
Example A, for instance, the investigators were prob-
ably searching for a few genes, or a few hundred at
most, worthy of intensive study for prostate cancer
etiology. I will assume
p0 ≥ 0.90(2.2)
in what follows, limiting the nonnull genes to no
more than 10%.
False discovery rate (Fdr) methods have devel-
oped in a strict frequentist framework, beginning
with Benjamini and Hochberg’s seminal 1995 paper,
but they also have a convincing Bayesian rationale
in terms of the two-groups model. Let F0(z) and
F1(z) denote the cumulative distribution functions
(cdf) of f0(z) and f1(z) in (2.1), and define the mix-
ture cdf F (z) = p0F0(z)+p1F1(z). Then Bayes’ rule
yields the a posteriori probability of a gene being in
the null group of (2.1) given that its z-value Z is
less than some threshold z, say “Fdr(z),” as
Fdr(z)≡ Pr{null|Z ≤ z}
(2.3)
= p0F0(z)/F (z).
[Here it is notationally convenient to consider the
negative end of the z scale, values like z =−3. Defi-
nition (2.3) could just as well be changed to Z > z or
Z > |z|.] Benjamini and Hochberg’s (1995) false dis-
covery rate control rule begins by estimating F (z)
with the empirical cdf
F¯ (z) =#{zi ≤ z}/N,(2.4)
yielding Fdr(z) = p0F0(z)/F¯ (z). The rule selects a
control level “q,” say q = 0.1, and then declares as
nonnull those genes having z-values zi satisfying zi ≤
z0, where z0 is the maximum value of z satisfying
Fdr(z0)≤ q(2.5)
[usually taking p0 = 1 in (2.3), and F0 the theoretical
null, the standard normal cdf Φ(z) of (1.1)].
The striking theorem proved in the 1995 paper
was that the expected proportion of null genes re-
ported by a statistician following rule (2.5) will be no
greater than q. This assumes independence among
the zi’s, extended later to various dependence mod-
els in Benjamini and Yekutieli (2001). The theorem
is a purely frequentist result, but as pointed out
in Storey (2002) and Efron and Tibshirani (2002),
it has a simple Bayesian interpretation via (2.3):
rule (2.5) is essentially equivalent to declaring non-
null those genes whose estimated tail-area posterior
probability of being null is no greater than q. It is
usually a good sign when Bayesian and frequentist
ideas converge on a single methodology, as they do
here.
Densities are more natural than tail areas for Baye-
sian fdr interpretation. Defining the mixture density
from (2.1),
f(z) = p0f0(z) + p1f1(z),(2.6)
Bayes’ rule gives
fdr(z)≡ Pr{null|Z = z}
(2.7)
= p0f0(z)/f(z)
for the probability of a gene being in the null group
given z-score z. Here fdr(z) is the local false discov-
ery rate (Efron et al., 2001; Efron, 2005).
There is a simple relationship between Fdr(z) and
fdr(z),
Fdr(z) =Ef{fdr(Z)|Z ≤ z},(2.8)
“Ef” indicating expectation with respect to the mix-
ture density f(z). That is, Fdr(z) is the mixture
average of fdr(Z) for Z ≤ z. In the usual situation
where fdr(z) decreases as |z| gets large, Fdr(z) will
be smaller than fdr(z). Intuitively, if we decide to la-
bel all genes with zi less than some negative value z0
as nonnull, then fdr(z0), the false discovery rate at
the boundary point z0, will be greater than Fdr(z0),
the average false discovery rate beyond the bound-
ary. Figure 2 illustrates the geometrical relationship
between Fdr(z) and fdr(z); the Benjamini–Hochberg
Fdr control rule amounts to an upper bound on the
secant slope.
For Lehmann alternatives
F1(z) = F0(z)
γ , [γ < 1],(2.9)
it turns out that
log
{
fdr(z)
1− fdr(z)
}
(2.10)
= log
{
Fdr(z)
1− Fdr(z)
}
+ log
(
1
γ
)
,
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Fig. 2. Relationship of Fdr(z) to fdr(z). Heavy curve plots numerator of Fdr, p0F0(z), versus denominator F (z); fdr(z) is
slope of tangent, Fdr slope of secant.
so
fdr(z) =˙Fdr(z)/γ(2.11)
for small values of Fdr. The prostate data of Fig-
ure 1 has γ about 1/2 in each tail, making fdr(z)∼
2 Fdr(z) near the extremes.
The statistics literature has not reached consen-
sus on the choice of q for the Benjamini–Hochberg
control rule (2.5)—what would be the equivalent of
0.05 for classical testing—but Bayes factor calcula-
tions offer some insight. Efron (2005, 2006) uses the
cutoff point
fdr(z)≤ 0.20(2.12)
for reporting nonnull genes, on the admittedly sub-
jective grounds that fdr values much greater than
0.20 are dangerously prone to wasting investigators’
resources. Then (2.6), (2.7) yield posterior odds ra-
tio
Pr{nonnull|z}/Pr{null|z}
= (1− fdr(z))/fdr(z)
(2.13)
= p1f1(z)/p0f0(z)
≥ 0.8/0.2 = 4.
Since (2.2) implies p1/p0 ≤ 1/9, (2.13) corresponds
to requiring Bayes factor
f1(z)/f0(z)≥ 36(2.14)
in favor of nonnull in order to declare significance.
Factor (2.14) requires much stronger evidence
against the null hypothesis than in standard one-
at-a-time testing, where the critical threshold lies
somewhere near 3 (Efron and Gous, 2001). The fdr
0.20 threshold corresponds to q-values in (2.5) be-
tween 0.05 and 0.15 for moderate choices of γ; such
q-value thresholds can be interpreted as providing
conservative Bayes factors for Fdr testing.
Model (2.1) ignores the fact that investigators usu-
ally begin with hot prospects in mind, genes that
have high prior probability of being interesting. Sup-
pose p0(i) is the prior probability that gene i is null,
and define p0 as the average of p0(i) over all N
genes. Then Bayes’ theorem yields this expression
for fdri(z) = Pr{genei null|zi = z}:
fdri(z) = fdr(z)
ri
1− (1− ri)fdr(z) ,
(2.15) [
ri =
p0(i)
1− p0(i)
/ p0
1− p0
]
,
where fdr(z) = p0f0(z)/f(z) as before. So for a hot
prospect having p0(i) = 0.50 rather than p0 = 0.90,
(2.15) changes an uninteresting result like fdr(zi) =
0.40 into fdri(zi) = 0.069.
Wonderfully neat and exact results like the Benjamini–
Hochberg Fdr control rule exert a powerful influence
on statistical theory, sometimes more than is good
for applied work. Much of the microarray statistics
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literature seems to me to be overly concerned with
exact properties borrowed from classical test the-
ory, at the expense of ignoring the complications
of large-scale testing. Neatness and exactness are
mostly missing in what follows as I examine an em-
pirical Bayes approach to the application of two-
groups/Fdr ideas to situations like those in Figure 1.
3. EMPIRICAL BAYES METHODS
In practice, the difference between Bayesian and
frequentist statisticians is their self-confidence in as-
signing prior distributions to complicated probabil-
ity models. Large-scale testing problems certainly
look complicated enough, but this is deceptive; their
massively parallel structure, with thousands of sim-
ilar situations each providing information, allows an
appropriate prior distribution to be estimated from
the data without upsetting even timid frequentists
like myself. This is the empirical Bayes approach of
Robbins and Stein, 50 years old but coming into its
own in the microarray era; see Efron (2003).
Consider estimating the local false discovery rate
fdr(z) = p0f0(z)/f(z), (2.7). I will begin with a “good”
case, like the prostate data of Example A in Section
1, where it is easy to believe in the theoretical null
distribution (1.1),
f0(z) = ϕ(z)≡ 1√
2π
e−(1/2)z
2
.(3.1)
The z-values in Example A were obtained by trans-
forming the usual two-sample t statistic “ti” com-
paring cancer and normal patients’ expression levels
for gene i, to a standard normal scale via
zi =Φ
−1(F100(ti));(3.2)
here Φ and F100 are the cdf’s of standard normal
and t100 distributions. If we had only gene i’s data
to test, classic theory would tell us to compare zi
with f0(z) = ϕ(z) as in (3.1).
For the moment I will take p0, the prior proba-
bility of a gene being null, as known. Section 4 dis-
cusses p0’s estimation, but in fact its exact value
does not make much difference to Fdr(z) or fdr(z),
(2.3) or (2.7), if p0 is near 1 as in (2.2). Benjamini
and Hochberg (1995) take p0 = 1, providing an up-
per bound for Fdr(z).
This leaves us with only the denominator f(z) to
estimate in (2.7). By definition (2.6), f(z) is the
marginal density of all N zi’s, so we can use all the
data to estimate f(z). The algorithm locfdr, an R
function available from the CRAN library, does this
by means of standard Poisson GLM software (Efron,
2005). Suppose the z-values have been binned, giv-
ing bin counts
yk =#{zi in bink}, k = 1,2, . . . ,K.(3.3)
The prostate data histogram in panel A of Figure 1
has K = 49 bins of width ∆= 0.2.
We take the yk to be independent Poisson counts,
yk
ind∼ P0(νk), k = 1,2, . . . ,K,(3.4)
with the unknown νk proportional to density f(z)
at midpoint “xk” of the kth bin, approximately
νk =N∆f(xk).(3.5)
Modeling log(νk) as a pth-degree polynomial func-
tion of xk makes (3.4)–(3.5) a standard Poisson gen-
eral linear model (GLM). The choice p = 7 used in
Figure 3 amounts to estimating f(z) by maximum
likelihood within the seven-parameter exponential
family
f(z) = exp
{
7∑
j=0
βjz
j
}
.(3.6)
Notice that p= 2 would make f(z) normal; the ex-
tra parameters in (3.6) allow flexibility in fitting
the tails of f(z). Here we are employing Lindsey ’s
method ; see Efron and Tibshirani (1996). Despite
its unorthodox look, it is no more than a conve-
nient way to obtain maximum likelihood estimates
in multiparameter families like (3.6).
The heavy curve in Figure 3 is an estimate of the
local false discovery rate for the prostate data,
f̂dr(z) = p0f0(z)/f̂ (z),(3.7)
with f̂(z) constructed as above, f0(z) = ϕ(z) as in
(3.1), and p0 = 0.93, as estimated in Section 4; f̂dr(z)
is near 1 for |z| ≤ 2, decreasing to interesting levels
for |z|> 3. Fifty-one of the 6033 genes have f̂dr(zi)≤
0.2, 26 on the right and 25 on the left, and these
could be reported back to the investigators as likely
nonnull candidates. [The standard Benjamini–
Hochberg procedure, (2.5) with q = 0.1, reports 60
nonnull genes, 28 on the right and 32 on the left.]
At this point the reader might notice an anomaly:
if p0 = 0.93 of the N genes are null, then about
(1− p0) · 6033 = 422 should be nonnull, but only 51
are reported. The trouble is that most of the non-
null genes are located in regions of the z axis where
f̂dr(zi) exceeds 0.5, and these cannot be reported
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Fig. 3. Heavy curve is estimated local false discovery rate f̂dr(z) for prostate data. Fifty-one genes, 26 on the right and 25
on the left, have f̂dr(zi)< 0.20. Vertical bars estimate histogram of the nonnull counts (plotted negatively, divided by 50). Most
of the nonnull genes will not be reported.
without also reporting a bevy of null cases. In other
words, the prostate study is underpowered.
The vertical bars in Figure 3 are estimates of the
nonnull counts, the histogram we would see if only
the nonnull genes provided z-values. In terms of
(3.3), (3.7), the nonnull counts “y
(1)
k ” are
y
(1)
k = [1− f̂drk]yk,(3.8)
where f̂drk = f̂dr(xk), the estimated fdr value at the
center of bin k. Since 1− f̂drk approximates the non-
null probability for a gene in bin k, formula (3.8) is
an obvious estimate for the expected number of non-
nulls.
Power diagnostics are obtained from comparisons
of f̂dr(z) with the nonnull histogram. High power
would be indicated if f̂drk was small where y
(1)
k was
large. That obviously is not the case in Figure 3. A
simple power diagnostic is
Ê fdr
(1)
=
K∑
k=1
y
(1)
k f̂drk
/ K∑
k=1
ŷ
(1)
k ,(3.9)
the expected nonnull fdr. We want Ê fdr
(1)
to be
small, perhaps near 0.2, so that a typical nonnull
gene will show up on a list of likely prospects. The
prostate data has Ê fdr
(1)
= 0.68, indicating low power.
If the whole study were rerun, we could expect a
different list of 50 likely nonnull genes, barely over-
lapping with the first list. Section 3 of Efron (2006)
discusses power calculations for microarray studies,
presenting more elaborate power diagnostics.
Stripped of technicalities, the idea underlying false
discovery rates is appealingly simple, and in fact
does not depend on the literal validity of the two-
groups model (2.1). Consider the bin zi ∈ [3.1,3.3] in
the prostate data histogram; 17 of the 6033 genes fall
into this bin, compared to expected number 2.68 =
p0N∆ϕ(3.2) of null genes, giving
fdr = 2.68/17 = 0.16(3.10)
as an estimated false discovery rate. (The smoothed
estimate in Figure 3 is f̂dr = 0.24.) The implication
is that only about one-sixth of the 17 are null genes.
This conclusion can be sharpened, as in Lehmann
and Romano (2005), but (3.10) catches the main
idea.
Notice that we do not need all the null genes to
have the same density f0(z); it is enough to as-
sume that the average null density is f0(z), ϕ(z) in
this case, in order to calculate the numerator 2.68.
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Table 1
Boldface, standard errors of log f̂dr(z), (local fdr), and
log F̂dr(z), (tail-area), 250 replications of model (3.11),
N = 1500. Parentheses, average from formula (5.9), Efron
(2006); fdr is true value (2.7). Empirical Null results
explained in Section 4
Theoretical null Empirical null
z fdr local (formula) tail local (formula) tail
1.5 0.88 0.05 (0.05) 0.05 0.04 (0.04) 0.10
2.0 0.69 0.08 (0.09) 0.05 0.09 (0.10) 0.15
2.5 0.38 0.09 (0.10) 0.05 0.16 (0.16) 0.23
3.0 0.12 0.08 (0.10) 0.06 0.25 (0.25) 0.32
3.5 0.03 0.10 (0.13) 0.07 0.38 (0.38) 0.42
4.0 0.005 0.11 (0.15) 0.10 0.50 (0.51) 0.52
(This is an advantage of false discovery rate meth-
ods, which only control rates, not individual proba-
bilities.) The nonnull density f1(z) in (2.1) plays no
role at all since the denominator 17 is an observed
quantity. Exchangeability is the key assumption in
interpreting (3.10): we expect about 1/6 of the 17
genes to be null, and assign posterior null probabil-
ity 1/6 to all 17. Nonexchangeability, in the form
of differing prior information among the 17, can be
incorporated as in (2.15).
Density estimation has a reputation for difficulty,
well-deserved in general situations. However, there
are good theoretical reasons, presented in Section
6 of Efron (2005), for believing that mixtures of
z-values are quite smooth, and that (3.7) will ef-
ficiently estimate fdr(z). Independence of the zi’s is
not required, only that f̂(z) is a reasonably close
estimate of f(z).
Table 1 reports on a small simulation study in
which
zi
ind∼ N(µi,1)

µi = 0,
with probability 0.9,
µi ∼N(3,1),
with probability 0.1,
(3.11)
for i= 1,2, . . . ,N = 1500. The table shows standard
deviations for log(f̂dr(z)), (3.7), from 250 simula-
tions of (3.11), and also using a delta-method for-
mula derived in Section 5 of Efron (2006), incor-
porated in the locfdr algorithm. Rather than (3.6),
f(z) was modeled by a seven-parameter natural spline
basis, locfdr ’s default, though this gave nearly the
same results as (3.6). Also shown are standard devia-
tions for the corresponding tail-area quantity
log(F̂dr(z)) obtained by substituting F̂ (z) =
∫ z
−∞ f̂(z
′)dz′ in (2.3). [This is a little less variable
than using F¯ (z), (2.4).]
The “Theoretical Null” side of the table shows
that f̂dr(z) is more variable than F̂dr(z), but both
are more than accurate enough for practical use. At
z = 3, for example, f̂dr(z) only errs by about 8%,
yielding f̂dr(z) =˙ 0.12 ± 0.01. Standard errors are
roughly proportional to N−1/2, so even reducing N
to 250 gives f̂dr(3) =˙ 0.12± .025, and similarly for
other values of z, accurate enough to make pictures
like Figure 3 believable.
Empirical Bayes is a bipolar methodology, with al-
ternating episodes of frequentist and Bayesian activ-
ity. Frequentists may prefer F̂dr [or Fdr, (2.5)] to f̂dr
because of connections with classical tail-area hy-
pothesis testing, or because cdf’s are more straight-
forward to estimate than densities, while Bayesians
prefer f̂dr for its more apt a posteriori interpretation.
Both, though, combine the Bayesian two-groups model
with frequentist estimation methods, and deliver the
same basic information.
A variety of local fdr estimation methods have
been suggested, using parametric, semiparametric,
nonparametric and Bayes methods: Pan et al. (2003),
Pounds and Morris (2003), Allison et al. (2002),
Heller and Qing (2003), Broberg (2005), Aubert et
al. (2004), Liao et al. (2004) and Do et al. (2005),
all performing reasonably well. The Poisson GLM
methodology of locfdr has the advantage of easy im-
plementation with familiar software, and a closed-
form error analysis.
Estimation efficiency becomes a more serious prob-
lem on the “Empirical Null” side of Table 1, where
we can no longer trust the theoretical null f0(z) ∼
N(0,1). This is the subject of Section 4.
4. THE EMPIRICAL NULL DISTRIBUTION
We have been assuming that f0(z), the null den-
sity in (2.1), is known on theoretical grounds, as in
(3.1). This leads to false discovery estimates such as
f̂dr(z) = p0f0(z)/f̂(z) and F̂dr(z) = p0F0(z)/F̂ (z),
where only denominators need be estimated. Most
applications of Benjamini and Hochberg’s control
algorithm (2.5) make the same assumption (some-
times augmented with permutation calculations,
which usually produce only minor corrections to the
theoretical null, as discussed in Section 5). Use of the
theoretical null is mandatory in classic one-at-a-time
testing, where theory provides the only information
available for null behavior. But things change in
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Fig. 4. z-values from two microarray studies. BRCA data (Hedenfalk et al., 2001), comparing seven breast cancer patients
having BRCA1 mutation to eight with BRCA2 mutation N = 3226 genes. HIV data (van’t Wout et al., 2003) comparing four
HIV+ males with four HIV− males, N = 7680 genes. Theoretical N(0,1) null, heavy curve is too narrow for BRCA data, too
wide for HIV data. Light curves are empirical nulls: normal densities fit to the central histogram counts.
large-scale simultaneous testing situations: serious
defects in the theoretical null may become obvious,
while empirical Bayes methods can provide more re-
alistic null distributions.
Figure 4 shows z-value histograms for two addi-
tional microarray studies, described more fully in
Efron (2006). These are of the same form as the
prostate data: n subjects in two disease categories
provide expression levels for N genes; two-sample t-
statistics ti comparing the categories are computed
for each gene, and then transformed to z-values zi =
Φ−1(Fn−2(ti)), as in (3.2). Unlike panel A of Figure
1, however, neither histogram obeys the theoretical
N(0,1) null near z = 0. The BRCA data has a much
wider central peak, while the HIV peak is too nar-
row. The lighter curves in Figure 4 are empirical null
estimates (Efron, 2004), normal curves fit to the cen-
tral peak of the z-value histograms. The idea here
is simple enough: we make the “zero assumption,”
Zero assumption.
Most of the z-values near
(4.1)
0 come from null genes,
(discussed further below), generalize theN(0,1) the-
oretical null to N(δ0, σ
2
0), and estimate (δ0, σ
2
0) from
the histogram counts near z = 0. Locfdr uses two dif-
ferent estimation methods, analytical and geomet-
ric, described next.
Figure 5 shows the geometric method in action on
the HIV data. The heavy solid curve is log f̂(z), fit
from (3.6) using Lindsey’s method, as described in
Efron and Tibshirani (1996). The two-groups model
and the zero assumption suggest that if f0 is nor-
mal, f(z) should be well-approximated near z = 0
by p0ϕδ0,σ0(z), with
ϕδ0,σ0(z)≡ (2πσ20)−1/2 exp
{
−1
2
(
z − δ0
σ0
)2}
,(4.2)
making log f(z) approximately quadratic,
log f(z) =˙ log p0 − 1
2
{
δ20
σ20
+ log(2πσ20)
}
(4.3)
+
δ0
σ20
z − 1
2σ20
z2.
The beaded curve shows the best quadratic approx-
imation to log f̂(z) near 0. Matching its coefficients
10 B. EFRON
Fig. 5. Geometric estimate of null proportion p0 and empirical null mean and standard deviation (δ0, σ0) for the HIV data.
Heavy curve is log f̂(z), estimated as in (3.3)–(3.6); beaded curve is best quadratic approximation to log f̂(z) near z = 0.
(β̂0, β̂1, β̂2) to (4.3) yields estimates (δ̂0, σ̂0, p̂0), for
instance, σ̂0 = (2β̂2)
−1/2,
δ̂0 =−0.107,
σ̂0 = 0.753,(4.4)
p̂0 = 0.931,
for the HIV data. Trying the same method with the
theoretical null, that is, taking (δ0, σ0) = (0,1) in
(4.3), gives a very poor fit, and p̂0 equals the impos-
sible value 1.20.
The analytic method makes more explicit use of
the zero assumption, stipulating that the nonnull
density f1(z) in the two-groups model (2.1) is sup-
ported outside some given interval [a, b] containing
zero (actually chosen by preliminary calculations).
Let N0 be the number of zi in [a, b], and define
P0(δ0, σ0) = Φ
(
b− δ0
σ0
)
−Φ
(
a− δ0
σ0
)
and
(4.5)
θ = p0P0.
Then the likelihood function for z0, the vector of N0
z-values in [a, b], is
fδ0,σ0,p0(z0) = [θ
N0(1− θ)N−N0]
(4.6)
·
[ ∏
zi∈z0
ϕδ0,σ0(zi)
P0(δ0, σ0)
]
.
This is the product of two exponential family like-
lihoods, which is numerically easy to solve for the
maximum likelihood estimates (δ̂0, σ̂0, p̂0), equaling
(−0.120,0.787,0.956) for the HIV data.
Both methods are implemented in locfdr. The an-
alytic method is somewhat more stable but can be
more biased than geometric fitting. Efron (2004)
shows that geometric fitting gives nearly unbiased
estimates of δ0 and σ0 for p0 ≥ 0.90. Table 2 shows
how the two methods fared in the simulation study
of Table 1.
A healthy literature has sprung up on the estima-
tion of p0, as in Pawitan et al. (2005) and Langlass
et al. (2005), all of which assumes the validity of
the theoretical null. The zero assumption plays a
Table 2
Comparison of estimates (δ̂0, σ̂0, p̂0), simulation study of
Table 1. “Formula” is average from delta-method standard
deviation formulas, Section 5 in Efron (2006), as
implemented in locfdr
Geometric Analytic
mean stdev (formula) mean stdev (formula)
δ̂0: 0.02 0.056 (0.062) 0.04 0.031 (0.032)
σ̂0: 1.02 0.029 (0.033) 1.04 0.031 (0.031)
p̂0: 0.92 0.013 (0.015) 0.93 0.009 (0.011)
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central role in this literature [which mostly works
with two-sided p-values rather than z-values, e.g.,
pi = 2(1 − F100(|ti|)) in (3.2), making the “zero re-
gion” occur near p = 1]. The two-groups model is
unidentifiable if f0 is unspecified in (2.1), since we
can redefine f0 as f0+cf1, and p1 as p1−cp0 for any
c≤ p1/p0. With p1 small, (2.2), and f1 supposed to
yield zi’s far from 0 for the most part, the zero as-
sumption is a reasonable way to impose identifiabil-
ity on the two-groups model. Section 6 considers the
meaning of the null density more carefully, among
other things explaining the upward bias of p̂0 seen
in Table 2.
The empirical null is an expensive luxury from
the point of view of estimation efficiency. Compar-
ing the right-hand side of Table 1 with the left re-
veals factors of 2 or 3 increase in standard error rel-
ative to the theoretical null, near the crucial point
where fdr(z) = 0.2. Section 4 of Efron (2005) pins
the increased variability entirely on the estimation
of (δ0, σ0); even knowing the true values of p0 and
f(z) would reduce the standard error of log f̂dr(z)
by less than 1%. (Using tail-area Fdr’s rather than
local fdr’s does not help—here the local version is
less variable.)
The reason for considering empirical nulls is that
the theoretical N(0,1) null does not seem to fit the
data in situations like Figure 4. For the BRCA data
we can see that the histogram is overdispersed com-
pared to N(0,1) around z = 0; the implication is
that there will be more null counts far from zero
than the theoretical null predicts, making N(0,1)
false discovery rate calculations like (3.10) too opti-
mistic. The opposite happens with the HIV data.
There is a lot at stake here for both Bayesians
and frequentists. Table 3 shows the number of gene
discoveries identified by the standard Benjamini–
Hochberg two-sided Fdr procedure, q = 0.10 in (2.5).
The HIV results are much more dramatic using the
empirical null f0(z) ∼ N(−0.11,0.752) and in fact
we will see in the next section that σ0 = 0.75 is quite
believable in this case. The BRCA data has been
used in the microarray literature to compare anal-
ysis techniques, under the presumption that better
techniques will produce more discoveries; recently,
for instance, in Storey et al. (2005) and Pawitan et
al. (2005). Table 3 suggests caution in this interpre-
tation, where using the empirical null negates any
discoveries at all.
The z-values in panel C of Figure 1, proteomics
data, were calculated from standard Cox likelihood
Table 3
Number of genes identified as true discoveries by two-sided
Benjamini–Hochberg procedure, 0.10 control level
Theoretical null Empirical null
BRCA data: 107 0
HIV data: 22 180
Empirical null densities as in Figure 4.
tests that should yield N(0,1) null results asymp-
totically. A N(−0.02,1.292) empirical null was ob-
tained from the analytic method, resulting in only
one peak with f̂dr < 0.2; using the theoretical null
gave six such peaks.
In panel B of Figure 1, the z-values were obtained
from familiar binomial calculations, each zi being
calculated as
z = (p̂ad − p̂dis−∆)
(4.7)
·
(
p̂ad(1− p̂ad)
nad
+
p̂dis(1− p̂dis)
ndis
)−1/2
,
where nad was the number of advantaged students in
the high school, p̂ad the proportion passing the test,
and likewise ndis and p̂dis for the disadvantaged stu-
dents; ∆ = 0.192 was the overall difference, median
(p̂ad)−median (p̂dis). Here the empirical null stan-
dard deviation σ̂0 equals 1.52, half again bigger than
the theoretical standard deviation we would use if
we had only one school’s data. An empirical null fdr
analysis yielded 75 schools with f̂dr < 0.20, 30 on
the left and 45 on the right. Example B is discussed
a bit further in the next two sections, where its use
in the two-groups model is questioned.
My point here is not that the empirical null is
always the correct choice. The opposite advice, al-
ways use the theoretical null, has been inculcated by
a century of classic one-case-at-a-time testing to the
point where it is almost subliminal, but it exposes
the statistician to obvious criticism in situations like
the BRCA and HIV data. Large-scale simultaneous
testing produces mass information of a Bayesian na-
ture that impinges on individual decisions. The two-
groups model helps bring this information to bear,
after one decides on the proper choice of f0 in (2.1).
Section 5 discusses this choice, in the form of a list of
reasons why the theoretical null, and its close friend
the permutation null, might go astray.
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5. THEORETICAL, PERMUTATION AND
EMPIRICAL NULL DISTRIBUTIONS
Like most statisticians, I have spent my profes-
sional life happily testing hypotheses against theo-
retical null distributions. It came as somewhat of a
shock then, when pictures like Figure 4 suggested
that the theoretical null might be more theoreti-
cal than I had supposed. Once suspicious, it be-
comes easy to think of reasons why f0(z), the cru-
cial element in the two-groups model (2.1), might
not obey classical guidelines. This section presents
four reasons why the theoretical null might fail, and
also gives me a chance to say something about the
strengths and weaknesses of permutation null distri-
butions.
Reason 1 (Failed mathematical assumptions).
The usual derivation of the null hypothesis distri-
bution for a two-sample t-statistic assumes inde-
pendent and identically distributed (i.i.d.) normal
components. For the BRCA data of Figure 4, di-
rect inspection of the 3226 by 15 matrix “X” of
expression values reveals markedly nonnormal com-
ponents, skewed to the right (even after the columns
of X have been standardized to mean 0 and stan-
dard deviation 1, as in all my examples here). Is this
causing the failure of the N(0,1) theoretical null?
Permutation techniques offer quick relief from such
concerns. The columns ofX are randomly permuted,
giving a matrix X∗ with corresponding t-values t∗i
and z-values z∗i =Φ
−1(Fn−2(t∗i )). This is done some
large number of times, perhaps 100, and the empiri-
cal distribution of the 100 ·N z∗i ’s used as a permuta-
tion null. The well-known SAM algorithm (Tusher,
Tibshirani and Chu, 2001) effectively employs the
permutation null cdf in the numerator of the Fdr
formula (2.3).
Applied to the BRCA matrix, the permutation
null came out nearly N(0,1) (as did simply simulat-
ing the entries of X∗ by independent draws from all
3226 · 15 entries of X), so nonnormal distributions
were not the cause of BRCA’s overwide histogram.
In practice the permutation null usually approxi-
mates the theoretical null closely, as a long history
of research on the permutation t-test demonstrated;
see Section 5.9 of Lehmann and Romano (2005).
Reason 2 (Unobserved covariates). The BRCA
study is observational rather than experimental—
the 15 women were observed to be BRCA1 or BRCA2,
not assigned, and likewise with the HIV and prostate
studies. There are likely to be covariates—age, race,
general health—that affect the microarray expres-
sion levels differently for different genes. If these
were known to us, they could be factored out using a
separate linear model on each gene’s data, providing
a new and improved zi obtained from the “Treat-
ment” coefficient in the model. This would reduce
the spread of the z-value histogram, perhaps even
restoring the N(0,1) theoretical null for the BRCA
data.
Unobserved covariates act to broaden the null dis-
tribution f0(z). They also broaden the nonnull dis-
tribution f1(z) in (2.1), and the mixture density
f(z), but this does not correct fdr estimates like
(3.10), where the numerator, which depends entirely
on f0, is the only estimated quantity. Section 4 of
Efron (2004) provides an analysis of a simplified
model with unobserved covariates. Permutation tech-
niques cannot recognize unobserved covariates, as
the model demonstrates.
Reason 3 (Correlation across arrays). False dis-
covery rate methodology does not require indepen-
dence among the test statistics zi. However, the the-
oretical null distribution does require independence
of the expression values used to calculate each zi;
in terms of the elements xij of the expression ma-
trix X , for gene i we need independence among
xi1, xi2, . . . , xin in order to validate (1.1).
Experimental difficulties can undercut across-
microarray independence, while remaining undetect-
able in a permutation analysis. This happened in
both studies of Figure 4 (Efron, 2004, 2006). The
BRCA data showed strong positive correlations among
the first four BRCA2 arrays, and also among the last
four. This reduces the effective degrees of freedom
for each t-statistic below the nominal 13, making ti
and zi =Φ
−1(F13(ti)) overdispersed.
Reason 4 (Correlation across genes). Benjamini
and Hochberg’s 1995 paper verified Fdr control for
rule (2.5) under the assumption of independence
among the N z-values (relaxed a little in Benjamini
and Yekutieli, 2001). This seems fatal for microar-
ray applications since we expect genes to be corre-
lated in their actions. A great virtue of the empirical
Bayes/two-groups approach is that independence is
not necessary; with F̂dr(z) = p0F0(z)/F̂ (z), for in-
stance, F̂dr(z) can provide a reasonable estimate of
Pr{null|Z ≤ z} as long as F̂ (z) is roughly unbiased
for F (z)—in formal terms requiring consistency but
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not independence—and likewise for the local version
f̂dr(z) = p0f0(z)/f̂ (z), (3.7).
There is, however, a black cloud inside the silver
lining: the assumption that the null density f0(z) is
known to the statistician. The empirical null esti-
mation methods of Section 4 do not require z-value
independence, and so disperse the black cloud, at
the expense of increased variability in fdr estimates.
Do we really need to use an empirical null? Efron
(2007) discusses the following somewhat disconcert-
ing result: even if the theoretical null distribution
zi ∼ N(0,1) holds exactly true for all null genes,
Reasons 1–3 above not causing trouble, correlation
among the zi’s can make the overall null distribu-
tion effectively much wider or much narrower than
N(0,1).
Microarray data sets tend to have substantial z-
value correlations. Consider the BRCA data: there
are more than five million correlations ρij between
pairs of gene z-values zi and zj ; by examining the
row-wise correlations in the X matrix we can esti-
mate that the distribution of the ρij ’s has approxi-
mately mean 0 and variance α2 = 0.1532,
ρ∼ (0, α2).(5.1)
(The zero mean is a consequence of standardizing
the columns of X .) This is a lot of correlation—as
much as if the BRCA genes occurred in 10 indepen-
dent groups, but with common interclass correlation
0.50 for all genes within a group.
Section 3 of Efron (2006) shows that under as-
sumptions (1.1)–(5.1), the ensemble of null-gene z-
values will behave roughly as
zi∼˙N(0, σ20)(5.2)
with
σ20 = 1+
√
2A, A∼ (0, α2).(5.3)
If the variable A equaled α = 0.153, for instance,
giving σ0 = 1.10, then the expected number of null
counts below z =−3 would be about p0NΦ(−3/1.10)
rather than p0NΦ(−3), more than twice as many.
There is even more correlation in the HIV data,
α =˙ 0.42, enough so that a moderately negative
value of A could cause σ0 = 0.75, as in Figure 4.
The random variable A acts like an observable an-
cillary in the two-groups situation—observable be-
cause we can estimate σ0 from the central counts of
the z-value histogram, as in Section 4; σ̂0 is essen-
tially the half-width of the central peak.
Figure 6 is a cautionary story on the dangers of
ignoring σ̂0. A simulation model with
zi ∼N(0,1), i= 1,2, . . . ,2700, and
(5.4)
zi ∼N(2.5,1.5), i= 2701, . . . ,3000,
was run, in which the null zi’s, the first 2700, were
correlated to the same degree as in the BRCA data,
α = 0.153. For each of 1000 simulations of (5.4),
a standard Benjamini–Hochberg Fdr analysis (2.5)
(i.e., using the theoretical null for F0) was run at
control level q = 0.10, and used to identify a set of
nonnull genes.
Each of the thousand points in Figure 6 is (σ̂0,Fdp),
where σ̂0 is half the distance between the 16th and
86th percentiles of the 3000 zi’s, and Fdp is the
“False discovery proportion,” the proportion of iden-
tified genes that were actually null. Fdp averaged
0.091, close to the target value q = 0.10, but with a
strong dependence on σ̂0: the lowest 5% of σ̂0’s cor-
responded to Fdp’s averaging only 0.03, while the
upper 5% average was 0.29, a factor of 9 difference.
The point here is not that the claimed q-value 0.10
is wrong, but that in any one simulation we may
be able to see, from σ̂0, that it is probably mislead-
ing. Using the empirical null counteracts this fallacy
which, again, is not apparent from the permutation
null. (Section 4 of Efron, 2007, discusses more elab-
orate permutation methods that do bear on Figure
6. See Qui et al., 2005, for a gloomier assessment of
correlation effects in microarray analyses.)
What is causing the overdispersion in the Edu-
cation data of panel B, (4.7)? Correlation across
schools, Reason 44, seems ruled out by the nature of
the sampling, leaving Reasons 2 and 3 as likely can-
didates; unobserved covariates are an obvious threat
here, while within-school sampling dependences (Rea-
son 3) are certainly possible. Fdr analysis yields
eight times as many “significant” schools based on
the theoretical null rather than f0 ∼N(−0.35,1.512),
but looks completely untrustworthy to me.
Sometimes the theoretical null distribution is fine,
of course. The prostate data had (δ̂0, σ̂0) = (0.00,1.06)
according to the analytic method of (4.6), close enough
to (0,1) to make theoretical null calculations believ-
able. However, there are lots of things that can go
wrong with the theoretical null, and lots of data to
check it with in large-scale testing situations, mak-
ing it a matter of due diligence for the statistician to
do such checking, even if only by visual inspection
of the z-value histogram. All simultaneous testing
procedures, not just false discovery rates, go wrong
if the null distribution is misrepresented.
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Fig. 6. Benjamini–Hochberg Fdr control procedure (2.5), q = 0.1, run for 1000 simulations of correlated model (5.4); true
false discovery proportion Fdp plotted versus half-width estimate σ̂0. Overall Fdp averaged 0.091, close to q, but with a strong
dependence on σ̂0.
6. A ONE-GROUP MODEL
Classical one-at-a-time hypothesis testing depends
on having a unique null density f0(z), such as Stu-
dent’s t distribution for the normal two-sample sit-
uation. The assumption of unique f0 has been car-
ried over into most of the microarray testing litera-
ture, including our definition (2.1) of the two-groups
model.
Realistic examples of large-scale inference are apt
to be less clearcut, with true effect sizes ranging con-
tinuously from zero or near zero to very large. Here
we consider a “one-group” structural model that al-
lows for a range of effects. We can still usefully apply
fdr methods to data from one-group models; doing
so helps clarify the choice between theoretical and
empirical null hypotheses, and explicates the biases
inherent in model (2.1). The discussion in this sec-
tion, as in Section 2, will be mostly theoretical, in-
volving probability models rather than collections of
observed z-values.
Model (2.1) does not require knowing how the
z-values were generated, a substantial practical ad-
vantage of the two-groups formulation. In contrast,
one-group analysis begins with a specific Bayesian
structural model. We assume that the ith case has
an unobserved true value µi distributed according
to some density g(µ), and that the observed zi is
normally distributed around µi,
µ∼ g(·) and z|µ∼N(µ,1).(6.1)
The density g(µ) is allowed to have discrete atoms.
It might have an atom at zero but this is not re-
quired, and in any case there is no a priori partition
of g(µ) into null and nonnull components.
As an example, suppose g(µ) is a mixture of 90%
N(0,0.52) and 10% N(2.5,0.52),
g(µ) = 0.9 ·ϕ0,0.5(µ) + 0.1 ·ϕ2.5,0.5(µ)(6.2)
in notation (4.2). The histogram in Figure 7 shows
N = 3000 draws of µi from (6.2). I am thinking of
this as a situation having a large proportion of un-
interesting cases centered near, but not exactly at,
zero, and a small proportion of interesting cases cen-
tered far to the right. We still want to use the ob-
served zi’s from (6.2) to flag cases that are likely to
be interesting.
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Fig. 7. Left panel: Histogram shows N = 3000 draws of µi from model (6.2); smooth curve is corresponding density f(z),
(6.3). Right panel: “Emp null” is fdr(z) based on empirical null; it closely matches full Bayes posterior probability “Bayes”
= Pr{µk < 1.5|z} from (6.1)–(6.2); “Theo null” is fdr(z) based on theoretical null, a poor match to Bayes.
The density of z in model (6.1) is
f(z) =
∫ ∞
−∞
ϕ(µ− z)g(µ)dµ,
(6.3)
[ϕ(x) = exp(−x2/2)/
√
2π],
shown as the smooth curve in the left-hand panel,
f(z) = 0.9 ·ϕ0,1.12(z) + 0.1 ·ϕ2.5,1.12(z).(6.4)
The effect of noise in going from µi to zi ∼N(µi,1)
has blurred the strongly bimodal µ-histogram into
a smoothly unimodal f(z).
We can still employ the tactic of Figure 5, fitting a
quadratic curve to log f(z) around z = 0 to estimate
p0 and the empirical null density f0(z). Using the
formulas described later in this section gives
p0 = 0.93 and f0(z)∼N(.02,1.142),(6.5)
and corresponding fdr curve p0f0(z)/f(z), labeled
“Emp null” in the right-hand panel of Figure 7.
Looking at the histogram, it is reasonable to con-
sider “interesting” those cases with µi ≥ 1.5, and
“uninteresting” µi < 1.5. The curve labeled “Bayes”
in Figure 7 is the posterior probability
Pr{uninteresting|z} based on full knowledge of (6.1),
(6.2). The empirical null fdr curve provides an ex-
cellent estimate of the full Bayes result, without the
prior knowledge. [An fdr based on the theoretical
N(0,1) null is seen to be far off.]
Unobserved covariates, Reason 2 in Section 4, can
easily produce blurry null hypotheses like that in
(6.2). My point here is that the two-group model
will handle blurry situations if the null hypothesis is
empirically estimated. Or, to put things negatively,
theoretical or permutation null methods are prone
to error in such situations, no matter what kind of
analysis technique is used.
Comparing (6.5) with (6.4) shows that f0(z) is
just about right, but p0 is substantially larger than
the value 0.90 we might expect. The ϕ2.5,.5 com-
ponent of g(µ) puts some of its z-values near zero,
weakening the zero assumption (4.1) and biasing p0
upward. The same thing happened in Table 2 even
though model (3.11) is “unblurred,” g(µ) having a
point mass at µ= 0. Fortunately, p0 is the least im-
portant part of the two-groups model for estimat-
ing fdr(z), under assumption (2.2). “Bias” can be a
misleading term in model (6.1) since it presupposes
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that each µi is clearly defined as null or nonnull.
This seems clear enough in (3.11). The null/nonnull
distinction is less clear in (6.2), though it still makes
sense to search for cases that have µi unusually far
from 0.
The results in (6.5) come from a theoretical anal-
ysis of model (6.1). The idea in what follows is to
generalize the construction in Figure 5 by approxi-
mating ℓ(z) = log f(z) with Taylor series other than
quadratic.
The Jth Taylor approximation to ℓ(z) is
ℓJ(z) =
J∑
j=0
ℓ(j)(0)zj/j!,(6.6)
where ℓ(0)(0) = log f(0) and for j ≥ 1
ℓ(j)(0) =
dj log f(z)
dzj
∣∣∣∣
z=0
.(6.7)
Let f˜0(z) indicate the subdensity p0f0(z), the nu-
merator of fdr(z) in (2.7). The choice
f˜0(z) = e
ℓJ (z)(6.8)
matches f(z) at z = 0 (a convenient form of the zero
assumption) and leads to an fdr expression
fdr(z) = eℓJ (z)/f(z).(6.9)
Larger choices of J match f˜0(z) more accurately to
f(z), increasing ratio (6.9); the interesting z-values,
those with small fdr’s, are pushed farther away from
zero as we allow more of the data structure to be
explained by the null density.
Bayesian model (6.1) provides a helpful interpre-
tation of the derivatives ℓ(j)(0):
Lemma. The derivative ℓ(j)(0), (6.7), is the jth
cumulant of the posterior distribution of µ given z =
0, except that ℓ(2)(0) is the second cumulant minus
1. Thus
ℓ(1)(0) = E0 and
(6.10)
−ℓ(2)(0) = 1− V0 ≡ V¯0,
where E0 and V0 are the posterior mean and vari-
ance of µ given z = 0.
Proof of the lemma appears in Section 7 of Efron
(2005).
For J = 0,1,2, formulas (6.8), (6.9) yield simple
expressions for p0 and f0(z) in terms of f(0), E0
Table 4
Expressions for p0, f0 and fdr, first three choices of J in
(6.8), (6.9); V¯0 = 1− V0; J = 0 gives theoretical null, J = 2
empirical null; f(z) from (6.3)
J 0 1 2
p0 f(0)
√
2pi f(0)
√
2pieE
2
0
/2 f(0)
√
2pi
V¯0
eE
2
0
/2V¯0
f0(z) N(0,1) N(E0,1) N(E0/V¯0,1/V¯0)
fdr(z) f(0)e
−z2/2
f(z)
f(0)eE0z−z
2/2
f(z)
f(0)eE0z−V¯0z
2/2
f(z)
and V¯0. These are summarized in Table 4, with p0
obtained from
p0 =
∫ ∞
−∞
f˜0(z)dz.(6.11)
Formulas are also available for Fdr(z), (2.8).
The choices J = 0,1,2 in Table 4 result in a nor-
mal null density f0(z), the only difference being the
means and variances. Going to J = 3 allows for an
asymmetric choice of f0(z),
fdr(z) =
f(0)
f(z)
eE0z−V¯0z
2/2+S0z3/6,(6.12)
where S0 is the posterior third central moment of µ
given z = 0 in model (6.1). The program locfdr uses
a variant, the “split normal,” to model asymmetric
null densities, with the exponent of (6.12) replaced
by a quadratic spline in z.
The lemma bears on the difference between em-
pirical and theoretical nulls. Suppose that the prob-
ability mass of g(µ) occurring within a few units
of the origin is concentrated in an atom at µ = 0.
Then the posterior mean and variance (E0, V0) of µ
given z = 0 will be near 0, making (E0, V¯0)=˙(0,1).
In this case the empirical null (J = 2) will approx-
imate the theoretical null (J = 0). Otherwise the
two nulls differ; in particular, any mass of g(µ) near
zero increases V0, swelling the standard deviation
(1− V0)−1/2 of the empirical null.
The two-groups model (2.1), (2.2) puts one in a
hypothesis-testing frame of mind: a large group of
uninteresting cases is to be statistically separated
from a small interesting group. Even blurry situa-
tions like (6.2) exhibit a clear grouping, as in Figure
7. None of this is necessary for the one-group model
(6.1). We might, for example, suppose that g(µ) is
normal,
µ∼N(A,B2),(6.13)
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and proceed in an empirical Bayes way to estimate
A and B and then apply Bayes estimation to the
individual cases.
This line of thought leads directly to James–Stein
estimation (Efron and Morris, 1975). Estimation, as
opposed to testing, is the key word here—with pos-
sible effect sizes µi varying continuously rather than
having a large clump of values near zero. The Edu-
cation data of panel B, Figure 1, could reasonably
be analyzed this way, instead of through simultane-
ous testing. Scientific context, which says that there
is likely to be a large group of (nearly) unaffected
genes, as in (2.2), is what makes the two-groups
model a reasonable Bayes prior for microarray stud-
ies.
7. BAYESIAN AND FREQUENTIST
CONFIDENCE STATEMENTS
False discovery rate methods provide a happy mar-
riage between Bayesian and frequentist approaches
to multiple testing, as shown in Section 2. Empiri-
cal Bayes techniques based on the two-groups model
seem to give us the best of both statistical philoso-
phies. Things do not always work out so peaceably;
in these next two sections I want to discuss con-
tentious situations where the divorce court looms as
a possibility.
An insightful and ingenious paper by Benjamini
and Yekutieli (2005) discusses the following problem
in simultaneous significance testing: having applied
false discovery rate methods to select a set of nonnull
cases, how can confidence intervals be assigned to
the true effect size for each selected case? (The paper
and the ensuing discussion are much more general,
but this is all I need for the illustration here.)
Figure 8 concerns Benjamini and Yekutieli’s so-
lution applied to the following simulated data set:
N = 10,000 (µi, zi) pairs were generated as in (6.1),
with 90% of the µi zero, the null cases, and 10%
distributed N(−3,1),
g(µ) = 0.90 · δ0(µ) + 0.10 ·ϕ−3,1(µ),(7.1)
δ0(µ) a delta function at µ= 0. The Fdr procedure
(2.5) was applied with q0 = 0.05, yielding 566 non-
null “discoveries,” those having zi ≤−2.77.
The Benjamini–Yekutieli “false coverage rate”
(FCR) control procedure provides upper and lower
bounds for the true effect size µi corresponding to
each zi less than −2.77; these are indicated by heavy
diagonal lines in Figure 8, constructed as described
in BY’s Definition 1. This construction guarantees
that the expected proportion of the 566 intervals
not containing the true µi, the false coverage rate,
is bounded by q = 0.05.
In a real application only the zi’s and their BY
confidence intervals could be seen, but in a simula-
tion we can plot the actual (zi, µi) pairs, and com-
pare them to the intervals. Figure 8 plots (zi, µi) for
the 1000 nonnull cases, those from µi ∼ N(−3,1)
in (7.1). Of these, 55,2 plotted as heavy points, lie
to the left of z0 = −2.77, the Fdr threshold, with
the other 448 plotted as light points; 14 null cases,
µi = 0, plotted as “+,” also had zi < z0.
The first thing to notice is that the FCR property
is satisfied: only 17 of the 566 intervals have failed to
contain µi (14 of these the +’s), giving 3% noncover-
age. The second thing, though, is that the intervals
are frighteningly wide—zi ± 2.77, about
√
2 longer
than the usual individual 95% intervals zi ± 1.96—
and poorly centered, particularly at the left where
all the µi’s fall in their intervals’ upper halves.
An interesting comparison is with Bayes’ rule ap-
plied to (6.1), (7.1), which yields
Pr{µ= 0|zi}= fdr(zi),(7.2)
where
fdr(z) = 0.9 ·ϕ0,1(z)
(7.3)
· [0.9 ·ϕ0,1(z) + 0.1 ·ϕ−3,√2(z)]−1
as in (2.7), and
g(µi|µi 6= 0, zi)∼N
(
zi − 3
2
,
1
2
)
.(7.4)
That is, µi is null with probability fdr(zi), andN((zi−
3)/2, 1/2) with probability 1− fdr(zi). The dashed
lines indicate the posterior 95% intervals given that
µi is nonnull, (zi− 3)/2± 1.96/
√
2, now
√
2 shorter
than the usual individual intervals; at the top of
Figure 9 the beaded curve shows fdr(zi).
The frequentist FCR intervals and the Bayes in-
tervals are pursuing the same goal, to include the
nonnull scores µi with 95% probability. At zi =−2.77
the FCR assessment is Pr{µ ∈ [−5.54,0]} = 0.95;
Bayes’ rule states that µi = 0 with probability
fdr(−2.77) = 0.25, and if µi 6= 0, then µi ∈ [−4.27,
−1.49] with probability 0.95. This kind of discon-
nected description is natural to the two-groups model.
A principal cause of FCR’s oversized intervals (the
paper shows that no FCR-controlling intervals can
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Fig. 8. Benjamini–Yekutieli FCR controlling intervals applied to simulated sample of 10,000 cases from (6.1), (7.1). 566
cases have zi ≤ z0 =−2.77, the Fdr (0.05) threshold. Plotted points are (zi, µi) for the 1000 nonnull cases; 14 null cases with
zi ≤ z0 indicated by “+.” Heavy diagonal lines indicate FCR 95% interval limits; light lines are Bayes 95% posterior intervals
given µi 6= 0. Beaded curve at top is fdr(zi), posterior probability µi = 0.
Fig. 9. Computing a p-value for z¯S = 0.842, average of 15 z-values in CTL pathway, p53 data Solid histogram 500 row
randomizations give p-value 0.002. Line histogram 500 column permutations give p-value 0.048.
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be much narrower) comes from using a single con-
nected set to describe a disconnected situation.
Of course Bayes’ rule will not be easily available
to us in most practical problems. Is there an empir-
ical Bayes solution? Part of the solution certainly is
there: estimating fdr(z) as in Section 3. Estimating
g(µi|µi 6= 0, zi), (7.4), is more challenging. A straight-
forward approach uses the nonnull counts (3.8) to
estimate the nonnull density f1(z) in (2.1), decon-
volutes f̂1(z) to estimate the nonnull component
“g1(µ)” in (7.1), and applies Bayes’ rule directly to
ĝ1. This works reasonably well in Figure 8’s exam-
ple, but deconvolution calculations are notoriously
tricky and I have not been able to produce a stable
general algorithm.
Good frequentist methods like the FCR proce-
dure enjoy the considerable charm of an exact error
bound, without requiring a priori specifications, and
of course there is no law that they have to agree with
any particular Bayesian analysis. In large-scale sit-
uations, however, empirical Bayes information can
overwhelm both frequentist and Bayesian predilec-
tions, hopefully leading to a more satisfactory com-
promise between the two sets of intervals appearing
in Figure 8.
8. IS A SET OF GENES ENRICHED?
Microarray experiments, through a combination
of insufficient data per gene and massively multiple
simultaneous inference, often yield disappointing re-
sults. In search of greater detection power, enrich-
ment analysis considers the combined outcomes of
biologically defined sets of genes, such as pathways.
As a hypothetical example, if the 20 z-values in a
certain pathway all were positive, we might infer sig-
nificance to the pathway’s effect, whether or not any
of the individual zi’s were deemed nonnull.
Our example here will involve the p53 data, from
Subramanian et al. (2005), N = 10,100 genes on
n = 50 microarrays, zi’s as in (3.2), whose z-value
histogram looks like a slightly short-tailed normal
distribution having mean 0.04 and standard devia-
tion 1.06. Fdr analysis (2.5), q = 0.1, yielded just one
nonnull gene, while enrichment analysis indicated
seven or eight significant gene sets, as discussed at
length in Efron and Tibshirani (2006).
Figure 9 concerns the CTL pathway, a set of 15
genes relating to the development of so-called killer
T cells, #95 in a catalogue of 522 gene-sets provided
by Subramanian et al. (2005). For a given gene-set
“S” with m members, let z¯S denote the mean of the
m z-values within S ; z¯S is the enrichment statis-
tic suggested in the Bioconductor R package limma
(Smyth, 2004),
z¯S = 0.842(8.1)
for the CTL pathway. How significant is this result? I
will consider assigning an individual p-value to (8.1),
not taking into account multiple inference for a cat-
alogue of possible gene-sets (which we could correct
for later using Fdr methods, for instance, to combine
the individual p-values).
Limma computes p-values by “row randomization,”
that is, by randomizing the order of rows of the
N × n expression matrix X , and recomputing the
statistic of interest. For a simple average like (8.1)
this amounts to choosing random subsets of size
m = 15 from the N = 10,100 zi’s and comparing
z¯S to the distribution of the randomized values z¯∗S .
Five hundred rowrands produced only one z¯∗S > z¯S ,
giving p-value 1/500 = 0.002.
Subramanian et al. calculate p-values by permut-
ing the columns of X rather than the rows. The per-
mutations yield a much wider distribution than the
row randomizations in Figure 9, with correspond-
ing p-value 0.048. The reason is simple: the genes in
the CTL pathway have highly correlated expression
levels that increase the variance of z¯∗S ; column-wise
permutations of X preserve the correlations across
genes, while row randomizations destroy them.
At this point it looks like column permutations
should always give the right answer. Wrong! For the
BRCA data in Figure 4, the ensemble of z-values
has (mean, standard deviation) about (0,1.50), com-
pared to (0,1) for z∗i ’s from column permutations.
This shrinks the permutation variability of z¯∗S , com-
pared to what one would get from a random selec-
tion of genes for S , and can easily reverse the rela-
tionship in Figure 9.
The trouble here is that there are two obvious, but
different, null hypotheses for testing enrichment:
Randomization null hypothesis S has been chosen
by random selection of m genes from the full set of
N genes.
Permutation null hypothesis The order of the n
microarrays has been chosen at random with respect
to the patient characteristics (e.g., with the patient
being in the normal or cancer category in Example
A of the Introduction).
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Fig. 10. Enrichment analysis of Imaging data, panel D of Figure 1; z-value for original 15,445 voxels have been averaged
over “gene-sets” of neighboring voxels with city-block distance ≤ 2. Coded as “−” for z¯i < 0, “+” for z¯i ≥ 0; solid rectangles,
labeled as “Enriched,” show voxels with f̂dr(z¯i)≤ 0.2, using empirical null.
Efron and Tibshirani (2006) suggest a compro-
mise method, restandardization, that to some de-
gree accommodates both null hypotheses. Instead of
permuting z¯S in (8.1), restandardization permutes
(z¯S −µz)/σz , where (µz, σz) are the mean and stan-
dard deviation of all N zi’s. Subramanian et al. do
something similar using a Kolmogorov–Smirnov en-
richment statistic.
All of these methods are purely frequentistic. The-
oretically we might consider applying the two-groups/
empirical Bayes approach to sets of z-values “zS ,”
just as we did for individual zi’s in Sections 2 and
3. For at least three reasons that turns out to be
extremely difficult:
• My technique for estimating the mixture density
f , as in (3.6), becomes exponentially more diffi-
cult in higher dimensions.
• There is not likely to be satisfactory theoretical
null f0 for the correlated components of z¯S , while
estimating an empirical null faces the same “curse
of dimensionality” as for f .
• As discussed following (3.10), false discovery rate
interpretation depends on exchangeability, essen-
tially an equal a priori interest in all N genes.
There may be just one gene-set S of interest to
an investigator, or a catalogue of several hundred
S ’s as in Subramanian et al., but we certainly are
not interested in all possible gene-sets. It would
be a daunting exercise in subjective, as opposed
to empirical, Bayesianism to assign prior proba-
bilities to any particular gene-set S .
Having said this, it turns out there is one “gene-
set” situation where the two-groups/empirical Bayes
approach is practical (though it does not involve
genes). Looking at panel D of Figure 1, the Imag-
ing data, the obvious spatial correlation among z-
values suggests local averaging to reduce the effects
of noise.
This has been carried out in Figure 10: at voxel i
of the N = 15,445 voxels, the average of z-values for
those voxels within city-block distance 2 has been
computed, say “z¯i.” The results for the same hori-
zontal slice as in panel D are shown using a similar
symbol code. Now that we have a single number zi
for each voxel, we can compute the empirical null
f̂dr estimates as in Section 4. The voxels labeled “en-
riched” in Figure 10 are those having f̂dr(z¯i)≤ 0.2.
Enrichment analysis looks much more familiar in
this example, being no more than local spatial smooth-
ing. The convenient geometry of three-dimensional
space has come to our rescue, which it emphatically
fails to do in the microarray context.
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9. CONCLUSION
Three forces influence the state of statistical sci-
ence at any one time: mathematics, computation
and applications, by which I mean the type of prob-
lems subject-area scientists bring to us for solution.
The Fisher–Neyman–Pearson theory of hypothesis
testing was fashioned for a scientific world where
experimentation was slow and difficult, producing
small data sets focused on answering single ques-
tions. It was wonderfully successful within this mi-
lieu, combining elegant mathematics and limited com-
putational equipment to produce dependable answers
in a wide variety of application areas.
The three forces have changed relative intensi-
ties recently. Computation has become literally mil-
lions of times faster and more powerful, while scien-
tific applications now spout data in fire-hose quanti-
ties. (Mathematics, of course, is still mathematics.)
Statistics is changing in response, as it moves to ac-
commodate massive data sets that aim to answer
thousands of questions simultaneously. Hypothesis
testing is just one part of the story, but statistical
history suggests that it could play a central role:
its development in the first third of the twentieth
century led directly to confidence intervals, decision
theory and the flowering of mathematical statistics.
I believe, or maybe just hope, that our new scien-
tific environment will also inspire a new look at old
philosophical questions. Neither Bayesians nor fre-
quentists are immune to the pressures of scientific
necessity. Lurking behind the specific methodology
of this paper is the broader, still mainly unanswered,
question of how one should combine evidence from
thousands of parallel but not identical hypothesis
testing situations. What I called “empirical Bayes
information” accumulates in a way that is not well
understood yet, but still has to be acknowledged:
in the situations of Figure 4, the frequentist is not
free to stick with classical null hypotheses, while the
Bayesian cannot use prior (6.13), at least not with-
out the risk of substantial inferential confusion.
Classical statistics developed in a data-poor en-
vironment, as Fisher’s favorite description, “small-
sample theory,” suggests. By contrast, modern-day
disciplines such as machine learning seem to struggle
with the difficulties of too much data. Both prob-
lems, too little and too much data, can afflict mi-
croarray studies. Massive data sets like those in Fig-
ure 1 are misleadingly comforting in their sugges-
tion of great statistical accuracy. As I have tried to
show here, the power to detect interesting specific
cases, genes, may still be quite low. New methods
are needed, perhaps along the lines of “enrichment,”
as well as a theory of experimental design explicitly
fashioned for large-scale testing situations.
One floor up from the philosophical basement lives
the untidy family of statistical models. In this pa-
per I have tried to minimize modeling decisions by
working directly with z-values. The combination of
the two-groups model and false discovery rates ap-
plied to the z-value histogram is notably light on
assumptions, more so when using an empirical null,
which does not even require independence across the
columns of X (i.e., across microarrays, a dangerous
assumption as shown in Section 6 of Efron, 2004).
There will certainly be situations when modeling in-
side the X matrix, as in Newton et al. (2004) or
Kerr, Martin and Churchill (2000), yields more in-
formation than z-value procedures, but I will leave
that for others to discuss.
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